Mesoblast Ltd Class Action

The Claim

William Roberts Lawyers has filed a class action in the Federal Court against Mesoblast Limited (ASX: MSB) to recover compensation for persons who acquired an interest in Mesoblast shares traded on the Australian Stock Exchange (ASX) in the period from 22 February 2018 to 17 December 2020 (inclusive) (Relevant Period).

Anyone who acquired an interest in Mesoblast’s ASX shares during the Relevant Period may be entitled to compensation for losses arising out of Mesoblast’s alleged breaches of its continuous disclosure obligations and/or misleading and deceptive conduct.

The class action alleges that during the Relevant Period, Mesoblast engaged in unlawful conduct which misled the market about the company’s developmental stem cell product “remestemcel-L”. 

ICP Funding Pty Ltd and Investor Claim Partner Pty Ltd (ICP) are providing funding for the costs of the class action and management services, respectively.

Important Notice concerning group members’ rights

On 20 December 2023, the Federal Court of Australia made orders for the publication of an important notice to be provided to group members as well as other important documents, which can be accessed via the links below:

Notice to group members approved by the Court on 20 December 2023(PDF 27.9MB)

Amended Consolidated Originating Application (PDF 537.9KB)

Amended Consolidated Statement of Claim (PDF 1.1MB)

Amended Defence to the Amended Consolidated Statement of Claim (PDF 735.9KB)

Orders dated 20 December 2023 (PDF 1.1MB)

If you acquired an interest in Mesoblast shares during the Relevant Period, you will be notified by the Federal Court in due course of any steps you must take to participate. Additional information is available on the ICP website here